Calcilytix Therapeutics, Inc., A Bridgebio Company
Clinical trials sponsored by Calcilytix Therapeutics, Inc., A Bridgebio Company, explained in plain language.
A biotech company developing therapies for calcification-related diseases, owned by BridgeBio.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Can a pill restore calcium balance in hypoparathyroidism?
Disease control Recruiting nowThis phase 3 trial tests an oral drug called encaleret in about 160 adults with chronic hypoparathyroidism, a condition where the body makes too little parathyroid hormone, leading to low blood calcium and high urine calcium. Participants receive either encaleret or a placebo for…
Phase 3 • Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for kids with rare calcium disease: encaleret trial launches
Disease control Recruiting nowThis study tests a drug called encaleret in 28 children (birth to 17 years) with autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic condition causing low blood calcium. The goal is to see if the drug can safely raise calcium levels and reduce urinary calcium loss. Part…
Phase 2/3 • Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC